Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer

Carcinogenesis

Volumn 32, Issue 1, 2011, Pages 2-9

  Zhang, Bo ^a   Liu, Xiao Xiao ^b   He, Jian Rong ^b   Zhou, Ci Xiang ^a   Guo, Meng ^a,b   He, Ming ^a   Li, Mei Fang ^b   Chen, Guo Qiang ^a,b   Zhao, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; METADHERIN; MICRORNA 26A; TRANSCRIPTION FACTOR EZH2; TUMOR PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; MICRORNA; MIRN26A MICRORNA, HUMAN; MTDH PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER SIZE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; DNA FRAGMENTATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; DNA FRAGMENTATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 79952118835     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq209     Document Type: Article

References (37)

1. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
2. Chen,C.Z. (2005) MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med., 353, 1768-1771.
3. Calin,G.A. et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA, 101, 2999-3004.
4. Calin,G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
5. Iorio,M.V. et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 65, 7065-7070.
6. Kim,H. et al. (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc. Natl Acad. Sci. USA, 107, 2183-2188.
7. Kota,J. et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137, 1005-1017.
8. Sander,S. et al. (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood, 112, 4202-4212.
9. Zhang,L. et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad. Sci. USA, 103, 9136-9141.
10. Chen,L.C. et al. (1994) Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res., 54, 3021-3024.
11. Dahiya,R. et al. (1997) Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int. J. Cancer, 71, 20-25.
12. Huse,J.T. et al. (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev., 23, 1327-1337.
13. Ji,J. et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med., 361, 1437-1447.
14. Ciarapica,R. et al. (2009) Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle, 8, 172-175.
15. Maillot,G. et al. (2009) Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res., 69, 8332- 8340.
16. Lu,J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
17. Richardson,A.L. et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 9, 121-132.
18. Emdad,L. et al. (2009) Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc. Natl Acad. Sci. USA, 106, 21300-21305.
19. Kleer,C.G. et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA, 100, 11606-11611.
20. Li,J. et al. (2008) Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin. Cancer Res., 14, 3319-3326.
21. Kikuno,N. et al. (2007) Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene, 26, 7647-7655.
22. Liu,H. et al. (2009) Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells. J. Exp. Clin. Cancer Res., 28, 19.
23. Hu,G. et al. (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell, 15, 9-20.
24. Lee,S.G. et al. (2006) Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc. Natl Acad. Sci. USA, 103, 17390-17395.
25. Shi,B. et al. (2007) Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol., 27, 5105-5119.
26. Schuettengruber,B. et al. (2007) Genome regulation by polycomb and trithorax proteins. Cell, 128, 735-745.
27. Bracken,A.P. et al. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev., 21, 525-530.
28. Wagener,N. et al. (2008) The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int. J. Cancer, 123, 1545-1550.
29. Chen,C. et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res., 33, e179.
30. Yu,F. et al. (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-1123.
31. Suzuki,H.I. et al. (2009) Modulation of microRNA processing by p53. Nature, 460, 529-533.
32. Mazars,R. et al. (1992) p53 mutations occur in aggressive breast cancer. Cancer Res., 52, 3918-3923.
33. Grelier,G. et al. (2009) Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br. J. Cancer, 101, 673-683.
34. Bracken,A.P. et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J., 22, 5323-5335.
35. Luzi,E. et al. (2008) Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J. Bone Miner. Res., 23, 287-295.
36. Jones,M.R. et al. (2009) Zcchc11-dependent uridylation of microRNA directs cytokine expression. Nat. Cell Biol., 11, 1157-1163.
37. Yu,J. et al. (2007) A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ., 14, 436-446.